Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice

Oncogene

Volumn 22, Issue 4, 2003, Pages 517-527

  Lange, Karin ^a   Uckert, Wolfgang ^b   Blankenstein, Thomas ^b   Nadrowitz, Roger ^a   Bittner, Cordula ^a   Renauld, Jean Christophe ^c   Van Snick, Jacques ^c   Feller, Alfred C ^a   Merz, Hartmut ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Anaplastic lymphoma kinase (ALK); IL 9 transgenic mice; Retroviral mediated gene transfer; t(2; 5) translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COMPLEMENTARY DNA; HYBRID PROTEIN; INTERLEUKIN 9; NUCLEOPHOSMIN; RETROVIRUS VECTOR; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BONE MARROW CELL; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; THYMUS LYMPHOMA; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-9; LYMPHOMA, NON-HODGKIN; MICE; MICE, TRANSGENIC; PROTEIN-TYROSINE KINASES; RETROVIRIDAE;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0037473050     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206076     Document Type: Article

References (33)

1. Bischof D, Pulford K, Mason DY and Morris SW. (1997). Mol. Cell Biol., 17, 2312-2325.
2. Bittner C, Feller AC, Renauld JC, Lange K, Pietrzik R, Jenetzky C, Briese J, Gaiser T, Muller A, Wiedemann GJ, Van Snick J and Merz H. (2000). Lab. Invest., 80, 1523-1531.
3. Chomczynski P and Sacchi N. (1987). Anal. Biochem., 162, 156-159.
4. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, Al Saati T, Cerretti DP, Morris SW and Mason DY. (1997). Blood, 89, 1483-1490.
5. Demoulin JB and Renauld JC. (1998). Int. Rev. Immunol., 16, 345-364.
6. Dugas B, Renauld JC, Pene J, Bonnefoy JY, Peti-Frere C, Braquet P, Bousquet J, van Snick J and Mencia-Huerta JM. (1993). Eur. J. Immunol., 23, 1687-1692.
7. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S and Yamamoto T. (1996). Proc. Natl. Acad. Sci USA, 93, 4181-4186.
8. Graham FL and van der Eb AJ. (1973). Virology, 52, 456-467.
9. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY and Morris SW. (1997). Blood, 90, 2901-2910.
10. Ladanyi M. (1997). Cancer Surv., 30, 59-75.
11. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD and Fletcher JA. (2000). Am. J. Pathol., 157, 377-384.
12. Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME and Vardiman JW. (1989). Leukemia, 3, 866-870.
13. Look AT. (1997). Science, 278, 1059-1064.
14. Maes B, Vanhentenrijk V, Wlodarska I, Cools J, Peeters B, Marynen P and Wolf-Peeters C. (2001). Am. J. Pathol., 158, 2185-2193.
15. Markowitz D, Goff S and Bank A. (1988). J. Virol., 62, 1120-1124.
16. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hermelink HK and Van Snick J. (1991). Blood, 78, 1311-1317.
17. Miller AD and Rosman GJ. (1989). Biotechniques, 7, 980-986, 989.
18. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AI. (1994). Science, 263, 1281-1284.
19. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X and Witte DP. (1997). Oncogene, 14, 2175-2188.
20. Morris SW, Xue L, Ma Z and Kinney MC. (2001). Br. J. Haematol., 113, 275-295.
21. Petit-Frere C, Dugas B, Braquet P and Mencia-Huerta JM. (1993). Immunology, 79, 146-151.
22. Plowman GD, Sudarsanam S, Bingham J, Whyte D and Hunter T. (1999). Proc. Nat. Acad. Sci. USA, 96, 13603-13610.
23. Rabbitts TH. (2001). Oncogene, 20, 5763-5777.
24. Renauld JC, van der LN, Vink A, van Roon M, Godfraind C, Warnier G, Merz H, Feller A, Berns A and Van Snick J. (1994). Oncogene, 9, 1327-1332.
25. Renauld JC, Vink A, Louahed J and Van Snick J. (1995). Blood, 85, 1300-1305.
26. Robinson DR, Wu YM and Lin SF. (2000). Oncogene, 19, 5548-5557.
27. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT and Overbeek PA. (1991). Proc. Natl. Acad. Sci USA, 88, 2065-2069.
28. Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C, Delsol G, Mason D and Campo E. (2001). Lab. Invest., 81, 419-426.
29. Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T, Mason DY and Delsol G. (2000). Blood, 95, 3204-3207.
30. Uckert W, Pedersen L and Günzburg W. (2000). In: Walther W and Stein U (eds). Methods in Molecular Medicine, Vol. 35: Gene Therapy: Methods and Protocols. Human Press: Totowa, NJ. pp. 271-281.
31. Uyttenhove C, Druez C, Renauld JC, Herin M, Noel H and Van-Snick J. (1991). J. Exp. Med., 173, 519-522.
32. Vink A, Renauld JC, Warnier G and Van Snick J. (1993). Eur. J. Immunol., 23, 1134-1138.
33. Wellmann A, Doseeva V, Butscher W, Raffeld M, Fukushima P, Stetler-Stevenson M and Gardner K. (1997). FASEB J., 11, 965-972.